Intrinsiqq
Ironwood Pharmaceuticals Inc. logo

Ironwood Pharmaceuticals Inc.

IRWD

⊜ Compare

We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$578M
EPS$0.79
P/E4.43
P/FCF3.12
EV/EBITDA3.81
FCF Yield32.1%
Div. Yield–
Net Debt/FCF1.7x
Ironwood Pharmaceuticals Inc. intrinsic value
52-Week Range
$1.86$5.39

Profitability & Returns

Revenue (TTM)

$389M

▼ -15.7% YoY

Net Income (TTM)

$130M

▲ +2629.2% YoY

Op. Margin

60.15%

▲ +6.8pp YoY

ROIC

34.71%

▼ -21.3pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

$186M

▲ +22.8% YoY

Op. Cash Flow (TTM)

$186M

▲ +22.7% YoY

Net Debt

$318M

Cash & Equiv.

$79M

5Y CAGR: -5.3%

5Y CAGR: -5.3%

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with IRWD

CompareIntrinsic value
MNKDMannKind Corporation
$3.50+0.00%30
ESPREsperion Therapeutics Inc.
No recent price50
INVAInnoviva Inc.
$21.22-0.42%56
XERSXeris Biopharma Holdings, Inc.
$10.71-0.37%30
ZLABZai Lab Ltd
$22.07-1.30%40
ARDXArdelyx Inc.
$3.03-2.26%40
LQDALiquidia Corporation
$45.05+0.13%72
ORGOOrganogenesis Holdings Inc.
$0.77-6.21%50

Held by ETFs

IRWD is in 35 US ETFs. The largest of them, with IRWD's weight in each:

Ironwood Pharmaceuticals (IRWD) in four numbers

Fair value (earnings)
$5.49
Price $3.50 is 36% below it.
Intrinsic Value
Quality score
52/100
Best check: share count change, -10.3%. Weakest: cash flow growth, -9.3%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
4.43
Price to free cash flow 3.12.
Financials

Questions about Ironwood Pharmaceuticals

Is Ironwood Pharmaceuticals (IRWD) overvalued?

At $3.50, Ironwood Pharmaceuticals' price is 36% below the $5.49 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 4.43 times earnings and 3.12 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Ironwood Pharmaceuticals' fair value?

Intrinsiqq's calculator puts Ironwood Pharmaceuticals' fair value at $5.49 a share. It grows earnings per share 0% a year for 5 years, applies an exit P/E of 11.2, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.12. Every input can be changed on the Intrinsic Value tab.

Is Ironwood Pharmaceuticals a high-quality business?

Ironwood Pharmaceuticals scores 52 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 8 checks computed from SEC filings. Its best check is share count change at -10.3%, and its weakest is cash flow growth at -9.3%. The Quality tab shows every check against its target.

Does Ironwood Pharmaceuticals (IRWD) pay a dividend?

No. Ironwood Pharmaceuticals (IRWD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in IRWD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IRWD

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.